Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPM8 | Q7Z2W7 | 10/20 | 0.54 |
| ▸ | SLC6A4 | P31645 | 4/20 | 0.42 |
| ▸ | SLC6A3 | Q01959 | 4/20 | 0.42 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
| ▸ | ACP1 | P24666 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2060609 | 0.84 | TRPM8 (0.43) | TRPM8NR3C1 | |
| SCHEMBL2061062 | 0.84 | TRPM8 (0.44) | TRPM8NR3C1 | |
| SCHEMBL2061248 | 0.81 | TRPM8 (0.65) | TRPM8SLC6A4SLC6A3NR3C1ACP1 | |
| SCHEMBL2061065 | 0.81 | TRPM8 (0.79) | TRPM8SLC6A4SLC6A3 | |
| SCHEMBL2060894 | 0.81 | TRPM8 (0.65) | TRPM8SLC6A4SLC6A3NR3C1ACP1 | |
| SCHEMBL13262136 | 0.80 | TRPM8 (0.42) | TRPM8NR3C1 | |
| SCHEMBL2786001 | 0.80 | TRPM8 (0.42) | TRPM8NR3C1 | |
| SCHEMBL2061023 | 0.80 | TRPM8 (0.81) | TRPM8SLC6A4SLC6A3 | |
| SCHEMBL10280383 | 0.79 | TRPM8 (0.47) | TRPM8NR3C1 | |
| SCHEMBL1098674 | 0.78 | NR3C1 (0.54) | TRPM8NR3C1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8148422-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148422-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-03 | — | — | US | disclosed |
| US-8148422-B2 | Sulfonamides as TRPM8 modulators | JANSSEN PHARMACEUTICA, NV (BE) | 2012-04-03 | — | — | US | disclosed |
| WO-2010080398-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-07-15 | — | — | WO | disclosed |
| US-20100160289-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160289-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-24 | — | — | US | disclosed |
| US-20100160289-A1 | SULFONAMIDES AS TRPM8 MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2010-06-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100160289-A1 | SULFONAMIDES AS TRPM8 MODULATORS | TRPM8, TRPM2, TRPM5 | TRPM8 1/4885SLC6A4 635/4885SLC6A3 964/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.